<DOC>
	<DOCNO>NCT01849497</DOCNO>
	<brief_summary>The primary objective study ass user ' ability administer full dose evolocumab home-use use either pre-filled syringe autoinjector/pen .</brief_summary>
	<brief_title>Study Assess In-home Use Evolocumab ( AMG 145 ) Using Prefilled Syringe Prefilled Autoinjector/Pen</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Fasting LDLC screen &gt; 85 mg/dL Fasting triglyceride less equal 400 mg/dL ( 4.5 mmol/L ) Exclusion Criteria : New York Heart Association ( NYHA ) III IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Type 1 diabetes poorly control type 2 diabetes Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>LDL-C , triglyceride , high cholesterol</keyword>
</DOC>